News | Lung Imaging | May 31, 2024

Medical imaging AI innovator debuts vision of  early lung cancer detection and care  

Qure.ai unveils its AI-powered lung cancer care continuum unveiled at ASCO 2024

May 31, 2024 — To further the fight against global lung cancer, Qure.ai, a leader in healthcare artificial intelligence (AI), will unveil its AI-powered lung cancer continuum at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, from May 31 to June 4, 2024.

Featuring AI solutions to identify, measure, manage, and monitor, the end-to-end care continuum is designed to support clinicians and advance developments for lung health in the pharmaceutical and medical device industries. 

“Lung cancer is the leading cause of cancer-deaths worldwide, with approximately 75% of patients detected in late-stage disease. Earlier detection reduces the need for therapeutic or surgical intervention and boosts survival rates, by over 90% if treatment starts at stage 1,” states Prashant Warier, CEO and Co-founder of Qure.ai.  

“Artificial intelligence for lung cancer powers early detection - not just as part of existing screening programs, but by finding small pulmonary nodules, often opportunistically, during general healthcare imaging procedures. This enables earlier identification and referral for imaging or treatment pathways. It also helps overcome the ongoing challenges of low lung cancer screening appointment uptake rates,” Prashant Warier adds. 

The Qure.ai lung cancer continuum provides regulatory-cleared* individual or end-to-end detection, analysis, and monitoring tools, putting improved patient care at the heart of innovation: 

·         AI to identify missed lung nodules from chest X-rays and support in early lung cancer diagnosis; 

·         AI to measure lung nodules via CT scans and track volumetric growth as part of progression monitoring; 

·         AI to manage lung cancer cases via multi-modality reporting, collaboration and prioritization tools; 

·         AI to monitor drug efficacy and disease progression in clinical trials and cancer care research. 

For more information: www.qure.ai 

*Global clearances such as FDA and EU MDR CE vary across geographies. 


Related Content

News | Artificial Intelligence

June 18, 2024 — The advancement of Artificial Intelligence (AI) in healthcare to support diagnostic decision making ...

Time June 18, 2024
arrow
News | Ultrasound Women's Health

June 18, 2024 — The International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) has announced details of ...

Time June 18, 2024
arrow
News | Artificial Intelligence

June 17, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care ...

Time June 17, 2024
arrow
News | Proton Therapy

June 14, 2024 — Atlantic Health System, an integrated health care system setting standards for quality health care in ...

Time June 14, 2024
arrow
News | PET Imaging

June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 14, 2024
arrow
News | PACS

June 13, 2024 — Cloud-PACS radiology solutions provider SynthesisHealth, Inc. has signed three new contracts with ...

Time June 13, 2024
arrow
News | Digital Radiography (DR)

June 12, 2024 — Carestream launched its Image Suite MR 10 Software to help deliver a boost to productivity and ...

Time June 12, 2024
arrow
News | Enterprise Imaging

June 12, 2024 — Mach7 Technologies, a company specializing in innovative medical imaging and data management solutions ...

Time June 12, 2024
arrow
News | SNMMI

June 11, 2024 — Heather Jacene, MD, assistant chief of Nuclear Medicine and Molecular Imaging at Brigham and Women’s ...

Time June 11, 2024
arrow
News | SNMMI

June 11, 2024 — The Society of Nuclear Medicine and Molecular Imaging recognized six new SNMMI Fellows during a plenary ...

Time June 11, 2024
arrow
Subscribe Now